Screener
Cogent Biosciences, Inc. COGT Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(97,352) | $(71,986) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 626 | 640 |
| Stock-based compensation expense | 16,908 | 10,008 |
| Amortization of operating leases, right-of-use assets | 529 | 498 |
| Net amortization (accretion) of premiums (discounts) on marketable securities | (1,180) | (955) |
| Amortization of debt discount and issuance costs | 278 | — |
| Loss on fixed asset disposal | 135 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Cogent Biosciences, Inc.'s stock-based comp?
- Cogent Biosciences, Inc. (COGT) reported stock-based comp of $16.91M in Q1 2026.
- How has Cogent Biosciences, Inc.'s stock-based comp changed year-over-year?
- Cogent Biosciences, Inc.'s stock-based comp increased by 68.9% year-over-year, from $10.01M to $16.91M.
- What is the long-term trend for Cogent Biosciences, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Cogent Biosciences, Inc.'s stock-based comp has grown at a 40.9% compound annual growth rate (CAGR), from $11.69M to $46.08M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Cogent Biosciences, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude